Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hypereosinophilic syndrome is a myeloproliferative disorder defined by unexplained, persistent hypereosinophilia with cutaneous or systemic involvement. We describe a patient with coexistence of hypereosinophilic syndrome and bullous pemphigoid. Treatment with the novel tyrosine kinase inhibitor imatinib mesylate resulted in durable remission of hypereosinophilia and skin lesions.
Hofmann
Silke C
SC
Department of Dermatology, University of Freiburg Freiburg, Germany.
Technau
Kristin
K
Müller
Antonia M S
AM
Lübbert
Michael
M
Bruckner-Tuderman
Leena
L
D000368:Aged; D001549:Benzamides; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate; D008297:Male; D010391:Pemphigoid, Bullous / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate